RMC-6236
RMC-6236 is a pharmaceutical drug with 7 clinical trials. Currently 7 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
7
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Clinical Trials (7)
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7